Home > Resources > Whitepapers > Silicones for pharmaceutical applications –analytical capabilities at Solvias

Silicones for pharmaceutical applications –analytical capabilities at Solvias

Silicones are used in pharmaceutical applications as part of formulations, as well as during manufacturing and in packaging. The term ‘silicones’ encompasses a large number of compounds based on polydialkylsiloxanes. The most common are trimethylsilyl-terminated polydimethylsiloxanes. Dimethicones and simethicones are used as active ingredients and antifoaming agents in numerous anti-flatulent or anti-acid formulations. In pharmaceutical formulations, while considered active ingredients, their effect is usually caused by their physical properties, as polydimethylsiloxanes are not metabolized.

Spotlight

Global Health Drug Discovery Institute

The Global Health Drug Discovery Institute (GHDDI) identifies and develops innovative approaches to new medicines for diseases most damaging to populations in the developing world. Diseases of particular focus are tuberculosis, malaria, diarrhea and parasitic infections etc. Being the first independent, not-for-profit research institute of its kind in China, GHDDI strives to establish a transformative drug discovery and translational platform with advanced biomedical research and development capabilities - from the bench to the bedside.

OTHER WHITEPAPERS

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Introducing EU Annex 1: Understanding the Newest Regulatory Requirements

whitePaper | July 1, 2023

As its title implies, Annex 1 is the European guidance document for good manufacturing practices of medicinal products. As such, it serves as the road map for sterile drug manufacturers to follow in order to arrive at the pathway to the highest level of sterility, assuring that their medicinal drug products deploy operational best practices, are certifiable, and regulatorily safe.

Prescription Drug Pricing: How Lack of Transparency Reduces Market Access, Utilization, and Adherence

whitePaper | November 25, 2019

It's clear that healthcare prices weigh heavily on the minds of Americans, and the time has come for the pharmaceutical industry to take the reins of the prescription drug pricing dialogue with consumers.

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Nanoform Management Presentation

whitePaper | May 24, 2022

Our proprietary nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics.

2020 Prescription Drug List

whitePaper | April 7, 2020

The information in this document is designed to help you understand the prescription drug benefits offered under this plan and to compare these benefits to those offered by other plans. Information contained in this summary is designed to help you compare both the value and scope offormulary benefits.

Silicones for pharmaceutical applications –analytical capabilities at Solvias